Cargando…
Therapeutic Strategies for Ovarian Cancer in Point of HGF/c-MET Targeting
Ovarian cancer is the fifth leading cause of cancer deaths in women and is regarded as one of the most difficult cancers to treat. Currently, studies are being conducted to develop therapeutic agents for effective treatment of ovarian cancer. In this review, we explain the properties of the hepatocy...
Autor principal: | |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9147666/ https://www.ncbi.nlm.nih.gov/pubmed/35630066 http://dx.doi.org/10.3390/medicina58050649 |
_version_ | 1784716863847006208 |
---|---|
author | Kim, Hyun Jung |
author_facet | Kim, Hyun Jung |
author_sort | Kim, Hyun Jung |
collection | PubMed |
description | Ovarian cancer is the fifth leading cause of cancer deaths in women and is regarded as one of the most difficult cancers to treat. Currently, studies are being conducted to develop therapeutic agents for effective treatment of ovarian cancer. In this review, we explain the properties of the hepatocyte growth factor (HGF)/mesenchymal-epithelial transition factor (c-MET) and how the signaling pathway of HGF/c-MET is activated in different cancers and involved in tumorigenesis and metastasis of ovarian cancer. We present the findings of clinical studies using small chemicals or antibodies targeting HGF/c-MET signaling in various cancer types, particularly in ovarian cancer. We also discuss that HGF/c-MET-targeted therapy, when combined with chemo drugs, could be an effective strategy for ovarian cancer therapeutics. |
format | Online Article Text |
id | pubmed-9147666 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-91476662022-05-29 Therapeutic Strategies for Ovarian Cancer in Point of HGF/c-MET Targeting Kim, Hyun Jung Medicina (Kaunas) Review Ovarian cancer is the fifth leading cause of cancer deaths in women and is regarded as one of the most difficult cancers to treat. Currently, studies are being conducted to develop therapeutic agents for effective treatment of ovarian cancer. In this review, we explain the properties of the hepatocyte growth factor (HGF)/mesenchymal-epithelial transition factor (c-MET) and how the signaling pathway of HGF/c-MET is activated in different cancers and involved in tumorigenesis and metastasis of ovarian cancer. We present the findings of clinical studies using small chemicals or antibodies targeting HGF/c-MET signaling in various cancer types, particularly in ovarian cancer. We also discuss that HGF/c-MET-targeted therapy, when combined with chemo drugs, could be an effective strategy for ovarian cancer therapeutics. MDPI 2022-05-11 /pmc/articles/PMC9147666/ /pubmed/35630066 http://dx.doi.org/10.3390/medicina58050649 Text en © 2022 by the author. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Review Kim, Hyun Jung Therapeutic Strategies for Ovarian Cancer in Point of HGF/c-MET Targeting |
title | Therapeutic Strategies for Ovarian Cancer in Point of HGF/c-MET Targeting |
title_full | Therapeutic Strategies for Ovarian Cancer in Point of HGF/c-MET Targeting |
title_fullStr | Therapeutic Strategies for Ovarian Cancer in Point of HGF/c-MET Targeting |
title_full_unstemmed | Therapeutic Strategies for Ovarian Cancer in Point of HGF/c-MET Targeting |
title_short | Therapeutic Strategies for Ovarian Cancer in Point of HGF/c-MET Targeting |
title_sort | therapeutic strategies for ovarian cancer in point of hgf/c-met targeting |
topic | Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9147666/ https://www.ncbi.nlm.nih.gov/pubmed/35630066 http://dx.doi.org/10.3390/medicina58050649 |
work_keys_str_mv | AT kimhyunjung therapeuticstrategiesforovariancancerinpointofhgfcmettargeting |